NASHUA, N.H. and SAN ANTONIO, Dec. 8, 2015 /PRNewswire/ -- iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that researchers will present updated data on the use of intraoperative radiation therapy (IORT) with the Xoft® Axxent® Electronic Brachytherapy (eBx®) System® for the treatment of early-stage breast cancer during the San Antonio Breast Cancer Symposium (SABCS) at the Henry B. Gonzalez Convention Center in San Antonio, Texas. The company also announced that more than 2,000 early-stage breast cancer patients have been treated to-date with IORT with the Xoft System. The Xoft System and its suite of products will be showcased at SABCS in the Xoft booth (#345) throughout the meeting from December 9-11.
"As more data emerges, IORT is becoming more widely adopted by an increasing variety of sites that recognize the number of patient benefits a shorter course of radiation offers," said Ken Ferry, CEO of iCAD. "We are committed to providing advanced treatment options like IORT that have the potential to transform the treatment of cancer for patients."
IORT is a procedure in which early-stage breast cancer is treated with just one dose of targeted radiation. Traditional breast cancer treatment involves daily radiation five days per week, for six to eight weeks. IORT allows radiation oncologists and breast cancer surgeons to work together to deliver a full, concentrated dose of radiation at the time of lumpectomy for eligible patients, targeting cancer cells and sparing healthy tissue, such as the heart, lungs, and ribs. A growing body of favorable clinical data supports the use of IORT in candidates meeting specific selection criteria. iCAD is currently conducting one of the largest IORT clinical studies to date using the Xoft System, which compares Xoft IORT to traditional external beam radiation therapy.
The Xoft System uses a proprietary miniaturized x-ray source, which is inserted into a flexible balloon-shaped applicator, then temporarily placed inside the lumpectomy cavity for the duration of the treatment, which can last as little as eight minutes. The procedure offers patients a number of unique benefits, including added convenience, reduced costs and fewer side effects, as compared to traditional treatment.
Updated data regarding Xoft IORT will also be revealed in a poster presentation during SABCS by Alam M. Nisar Syed, MD, Medical Director, Radiation Oncology and Endocurietherapy, Memorial Care Cancer Institute, Long Beach Memorial Medical Center. Dr. Syed will present his findings during the Radiotherapy Poster Session 3 on Thursday, December 10 from 5:00 to 7:00 pm. Dr. Syed will also be available from 12:00 to 1:00 pm at the Xoft booth (#345) on December 9 and December 10 to discuss his clinical experience treating patients with Xoft IORT. For updates throughout SABCS, follow the Xoft Twitter handle, @XoftiCAD. For information regarding Xoft and the technologies being discussed at SABCS 2015, please visit www.xoftinc.com.
About Xoft Axxent Electronic Brachytherapy System The Xoft System is an isotope-free radiation treatment that is FDA cleared, CE marked, and licensed in Canada for the treatment of cancer anywhere in the body, including treatment of early-stage breast cancer, gynecological cancers and non-melanoma skin cancer. It utilizes a proprietary miniaturized x-ray as the radiation source that delivers precise treatment directly to cancerous areas while sparing healthy tissue and organs. The Xoft System requires only minimal shielding and therefore does not require room redesign or construction investment. Minimal shielding also allows medical personnel to remain in the room with the patient during treatment. The mobility of the Xoft System makes it easy to treat patients at multiple locations and to easily store the system when not in use. Xoft is a wholly owned subsidiary of iCAD, Inc. For more information about Xoft visit www.xoftinc.com, like us on Facebook or follow us on Twitter at @xofticad.
About iCAD, Inc. iCAD delivers innovative cancer detection and radiation therapy solutions and services that enable clinicians to find and treat cancers earlier and faster while improving patient outcomes. iCAD offers a comprehensive range of upgradeable computer aided detection (CAD) and workflow solutions to support rapid and accurate detection of breast, prostate and colorectal cancers. iCAD's Xoft® Axxent® Electronic Brachytherapy (eBx®) System® is a painless, non-invasive technology that delivers high dose rate, low energy radiation, which targets cancer while minimizing exposure to surrounding healthy tissue. The Xoft System is FDA cleared, CE marked, and licensed in Canada for the treatment of cancer anywhere in the body, including treatment of early-stage breast cancer, gynecological cancers and non-melanoma skin cancer. The comprehensive iCAD technology platforms include advanced hardware and software as well as management services designed to support cancer detection and radiation therapy treatments. For more information, visit or www.icadmed.com or www.xoftinc.com.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995 Certain statements contained in this News Release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to the Company's ability to defend itself in litigation matters, to achieve business and strategic objectives, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, uncertainty of future sales levels, protection of patents and other proprietary rights, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence of products, increased competition, litigation and/or government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company's filings with the Securities and Exchange Commission. The words "believe", "demonstrate", "intend", "expect", "estimate", "will", "continue", "anticipate", "likely", "seek", and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC's website at http://www.sec.gov.
For iCAD media inquiries: Berry & Company Public Relations, LLC Jessica Burns, 212-253-8881 email@example.com
SOURCE iCAD, Inc.